Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 8/20 | 0.33 |
| ▸ | METAP1 | P53582 | 6/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13912232 | 0.81 | CA14 (0.48) | MEN1KMT2ABIRC2LMNACA14 | |
| SCHEMBL13912228 | 0.81 | CA14 (0.48) | MEN1KMT2ABIRC2LMNACA14 | |
| SCHEMBL14521614 | 0.81 | CA14 (0.48) | MEN1KMT2ABIRC2LMNACA14 | |
| SCHEMBL21488518 | 0.79 | GAA (0.39) | MEN1KMT2ACA14TSHRRECQL | |
| SCHEMBL21488489 | 0.78 | CA12 (0.35) | CNR2MEN1KMT2ABIRC2CA14 | |
| SCHEMBL13912230 | 0.76 | METAP2 (0.53) | METAP2METAP1KDM4EALDH1A1HPGD | |
| SCHEMBL13981338 | 0.74 | CA12 (0.39) | METAP2METAP1MEN1KMT2ACA14 | |
| SCHEMBL13985698 | 0.74 | CA12 (0.39) | METAP2METAP1MEN1KMT2ACA14 | |
| SCHEMBL13981339 | 0.74 | CA12 (0.39) | METAP2METAP1MEN1KMT2ACA14 | |
| SCHEMBL21488593 | 0.72 | CA2 (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190322618-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | XWPharma Ltd. (KY) | 2019-10-24 | — | — | US | claimed |
| EP-4384145-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPharma Ltd. (KY) | 2024-06-19 | — | — | EP | disclosed |
| US-20230285325-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPharma Ltd. (KY) | 2023-09-14 | — | — | US | disclosed |
| US-11690811-B2 | Pharmaceutical compositions and oral dosage forms of ketamine derivatives | XWPharma Ltd. (KY) | 2023-07-04 | — | — | US | disclosed |
| US-20230098084-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPharma Ltd. (KY) | 2023-03-30 | — | — | US | disclosed |
| WO-2023018966-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPharma Ltd. (KY) | 2023-02-16 | — | — | WO | disclosed |
| US-20190322618-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | XWPharma Ltd. (KY) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322618-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | OPRK1, KCNK10, KCNK17 | METAP2 4741/4885METAP1 4704/4885CNR2 199/4885 |
| US-11690811-B2 | Pharmaceutical compositions and oral dosage forms of ketamine derivatives | OPRK1, KCNK5, KCNK17 | METAP2 4639/4885METAP1 4678/4885CNR2 399/4885 |
| US-20230098084-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | OPRK1, KCNK5, KCNK17 | METAP2 4639/4885METAP1 4678/4885CNR2 399/4885 |
| US-20230285325-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | OPRK1, KCNK5, KCNK17 | METAP2 4639/4885METAP1 4678/4885CNR2 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.